Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 19/20 | 0.50 |
| ▸ | KIT | P10721 | 13/20 | 0.50 |
| ▸ | SRC | P12931 | 12/20 | 0.50 |
| ▸ | KDR | P35968 | 9/20 | 0.48 |
| ▸ | JAK3 | P52333 | 5/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.47 |
| ▸ | TEK | Q02763 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21416962 | 0.85 | LCK (0.53) | LCKKITSRCKDRJAK3 | |
| SCHEMBL5492585 | 0.76 | LCK (0.59) | LCKKITSRCKDRJAK3 | |
| SCHEMBL4753630 | 0.76 | LCK (0.47) | LCKKITSRCKDRJAK3 | |
| SCHEMBL5488850 | 0.73 | LCK (0.62) | LCKKITSRCKDRJAK3 | |
| SCHEMBL42089 | 0.72 | LCK (0.73) | LCKKITSRCKDRJAK3 | |
| SCHEMBL9939498 | 0.72 | ABL1 (0.65) | BRAFABL1 | |
| SCHEMBL5493973 | 0.72 | BRAF (0.60) | LCKKITSRCKDRJAK3 | |
| SCHEMBL5489073 | 0.71 | LCK (0.58) | LCKKITSRCKDRJAK3 | |
| SCHEMBL5497319 | 0.71 | LCK (0.65) | LCKKDRJAK3MAPK14TEK | |
| SCHEMBL14715547 | 0.69 | LCK (0.68) | LCKKITSRCKDRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | LCK 106/4885KIT 325/4885SRC 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.